Nevertheless, we should point out that low-dose 2DG reduced PD-1 expression (in agreement with [41]) and increased CD69 expression regardless of the timing of the treatment, which could also beneficially impact the anti-tumor T cell response by rendering the T cells less susceptible to inhibition via the PD-1/PD-L1 axis. The gene discussed is CD274; the disease is neoplasm.